Health Care · Services-Management Consulting Services

ASTH Astrana Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1083446137 filings
Russell 2000

ASTH at a glance

Astrana Health, Inc. (ASTH, SEC CIK 1083446) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Astrana Health, Inc. (ASTH) reported revenue of $3.2 billion (up 56.4% from FY2024) and net income of $22.5 million. Diluted EPS was $0.46.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Astrana Health, Inc. (ASTH) shares worth $723.8 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.2B
+56.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$723.8M · −2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Physician-centric, technology-powered, risk-bearing healthcare platform focused on value-based care delivery and coordination for 1.6 million patients
  • New emphasis on expanded Care Enablement segment integrating clinical, operational, financial, and administrative data via proprietary technology suite
  • Strategic shift to assume full financial risk through California Restricted Knox-Keene licensed health plans (RKKs) for broader professional and institutional risk management
  • Workforce growth stable with approximately 3,000 employees as of December 31, 2025, supporting over 20,000 contracted physicians in integrated network
  • Noteworthy expansion of employee development programs and increased community engagement including donations and volunteerism in 2025

Management Discussion & Analysis

  • Revenue $3.18B in 2025, up $1.15B vs $2.03B in 2024, ~56% YoY growth driven by acquisitions and organic growth
  • Adjusted EBITDA $205.4M, up from $170.4M in 2024, margin decreased to 6% from 8% YoY
  • Best segment: Prospect acquisition contributed significantly; worst unclear due to consolidated data only
  • Free cash flow $104.5M vs $44.2M prior year; $15.4M share repurchases, $7.9M dividends, $10.1M capex in 2025
  • Management highlights liquidity with $429.5M cash, $1.05B total debt, completed Prospect acquisition funded by $707.3M drawdown; sees sufficient liquidity for next 12 months

AI summary of the ASTH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New cybersecurity risk triggered by September 2026 Cybersecurity Incident involving social-engineering attempts and unauthorized information access
  • Legal and compliance exposure: ongoing litigation, regulatory scrutiny, breach notifications, fines and penalties from the Cybersecurity Incident
  • Operational risk: Prospect acquisition integration increases potential for information-security breaches across systems
  • Financial risk: continuing cybersecurity expert, remediation, litigation and notification costs may exceed insurance coverage
  • Third-party risk: service-provider cybersecurity failures could expose PHI/PII and disrupt operations

Management Discussion & Analysis

  • Revenue $1,023.6M, up 7% from $956.0M YoY, driven by capitation growth and full-risk enrollment
  • Operating margin 3.9% vs 2.0% YoY, with net income $20.3M vs $1.1M
  • Best segment Care Partners: revenue $968.8M, operating income $49.1M vs $25.3M
  • Worst segment Care Delivery: operating loss $1.6M vs $1.0M, despite revenue of $91.0M
  • Cash $396.2M vs $429.5M at December 31, 2025; operating cash flow $117.1M and debt repayments $115.9M
  • Near-term headwinds: cybersecurity remediation, litigation and notification costs remain unquantifiable; Georgia acquisition for $5.0M cash post-quarter

AI summary of the ASTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details

Item 7.01: Regulation FD Disclosure

  • Conference call and webcast scheduled for November 5, 2026 at 2:30 p.m. Pacific Time
  • Discussion covers financial results for the three and nine months ended September 30, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1,023.6M, up 7%, with adjusted EBITDA $77.2M, up 13%, signaling operating leverage
  • Net income attributable to Astrana $13.0M versus $0.4M, while adjusted EPS reached $0.71 versus $0.68

Item EX-99.2: Item EX-99.2

  • Q3 revenue $1,023.6M, up 7%, with capitation reaching $936.7M and signaling continued value-based care expansion
  • Adjusted EBITDA $77.2M, up 13%, while margin improved to 8% from 7%, indicating operating leverage
Filed Sep 23, 2026Full analysis →

Item 1.05: Material Cybersecurity Incidents

  • Material cybersecurity incident identified September 22, 2026, involving social engineering and unauthorized system access
  • Potential exposure of patient, employee, provider, credential, business, financial and intellectual-property information
Filed Sep 23, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation for conference and meeting use, signaling refreshed investor messaging
  • Exhibit 99.1 contains the substantive presentation materials and may include updated strategy or operating information

Item EX-99.1: Item EX-99.1

  • FY2026 revenue guidance $3.8–4.1B and Adjusted EBITDA guidance $255–280M, midpoint $267.5M
  • 2026E Adjusted EBITDA margin 6.8%, with targeted mid-to-high teens annual growth over the medium term

AI summaries of ASTH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ASTH

Don't miss the next ASTH filing

  • Alerts as it files. A push when ASTH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ASTH, by share count.
  • Ask anything. An AI agent that reads every ASTH filing and answers with sources.

ASTH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Vong JohnFNov 12, 2026$31.77
Vong JohnFOct 10, 2026$37.55
Sim BrandonFOct 6, 2026$37.00
Lam Thomas S.FOct 6, 2026$37.00
Basho ChandanFOct 2, 2026$35.88
Vong JohnFSep 15, 2026$38.35
Sim BrandonFSep 5, 2026$38.47
Basho ChandanFSep 5, 2026$38.47

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.0B$3.2B
Operating Income-$89.3M$78.5M
Net Income$60.7M$43.1M$22.5M
Op. Margin-4.4%2.5%
Net Margin-2.1%0.7%
Balance Sheet
Total Assets$933.4M$1.4B$2.2B
Equity-$712.7M$779.3M
ROE-6.1%2.9%
Per Share
EPS$1.29$0.90$0.46
Cash Flow
Operating CF-$52.2M$114.6M
CapEx$28.5M$8.0M$10.1M

Source: XBRL data in Astrana Health, Inc. (ASTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ASTH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ASTH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$723.8M
Q2 202627$927.6M
Q1 202628$420.1M
Q4 202528$441.4M
Q3 202528$517.9M
Q2 202526$440.6M
Q1 202523$372.7M
Q4 202420$326.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ASTH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 13, 2026--
4Oct 8, 2026--
4Oct 8, 2026--
4Oct 6, 2026--
8-KSep 23, 2026Analysis-
8-KSep 23, 2026Analysis-
4Sep 17, 2026--
8-KSep 15, 2026Analysis-
4Sep 9, 2026--
4Sep 8, 2026--
4Sep 1, 2026--
4Aug 18, 2026--
4Aug 11, 2026--
10-QAug 10, 2026Analysis
8-KAug 6, 2026Analysis-
SC 13GJul 31, 2026-
8-KJul 13, 2026Analysis-
8-KJul 1, 2026Analysis-
4Jun 30, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--

Related Health Care companies

All Health Care →

ASTH SEC filings: frequently asked questions

Which institutions hold ASTH stock?

As of September 30, 2026, the largest Astrana Health, Inc. (ASTH) holders among the 13F filers tracked by SignalX were BlackRock ($262.9 million), Vanguard Portfolio Management LLC ($92.3 million), Vanguard Capital Management LLC ($68.7 million), State Street Corp ($62.9 million), Dimensional Fund Advisors ($58.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ASTH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Astrana Health, Inc. (ASTH) reported revenue of $3.2 billion (up 56.4% from FY2024) and net income of $22.5 million. Diluted EPS was $0.46. The figures come from the XBRL data in the 10-K.

What did ASTH report in its latest 8-K?

Astrana Health, Inc. (ASTH) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

What are the latest ASTH SEC filings?

Astrana Health, Inc. (ASTH) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is ASTH's SEC CIK number?

Astrana Health, Inc. (ASTH)'s SEC Central Index Key (CIK) is 1083446. EDGAR lists every ASTH filing under that number.

Ask anything about ASTH

The research agent reads ASTH's filings, financials, insider trades and 13F holders, then answers with sources.